Wells Fargo Maintains Overweight on Edwards Lifesciences, Raises Price Target to $96

Benzinga · 1d ago
Wells Fargo analyst Larry Biegelsen maintains Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $95 to $96.